ACE-031 – 1mg

ACE-031

This product is not intended for weight loss, human consumption, or veterinary use. It is sold for research purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved.

What Is ACE-031 Peptide?

ACE-031, a recombinant fusion protein designed to inhibit myostatin and related ligands, has garnered attention for its potential to enhance muscle mass and strength. Myostatin, a member of the transforming growth factor-beta (TGF-β) superfamily, negatively regulates muscle growth. By binding to activin type II receptors, myostatin initiates signaling pathways that suppress muscle differentiation and growth. Inhibiting this pathway with ACE-031 can, therefore, promote muscle hypertrophy.(Wikipedia)

ACE-031 Peptide Benefits in Muscle Hypertrophy Research

In a study examining the effects of ACE-031 on suboccipital musculature in rats, a 16-week administration of the inhibitor led to significant muscle hyperplasia. This muscular activation was associated with increased intracranial pressure, suggesting a functional role of the myodural bridge in cerebrospinal fluid dynamics. The findings underscore the systemic effects of localized muscle growth and the importance of understanding the broader physiological implications of myostatin inhibition. (PubMed)

Further research into myostatin and its inhibitors has demonstrated that blocking this pathway can lead to substantial increases in muscle mass. For instance, a study involving mice treated with a soluble activin type IIB receptor, which functions similarly to ACE-031, showed muscle mass increases of up to 60%. These results highlight the potent anabolic effects of myostatin inhibition and its potential therapeutic applications. (Wikipedia)

ACE-031: Therapeutic Potential Beyond Muscle Growth

The therapeutic potential of ACE-031 extends beyond muscle hypertrophy. By promoting muscle growth, ACE-031 may offer benefits in conditions characterized by muscle wasting, such as muscular dystrophy or age-related sarcopenia. However, the systemic effects observed in studies, such as alterations in intracranial pressure, emphasize the need for comprehensive evaluations of safety and efficacy in long-term applications.

ACE-031 Peptide: Myostatin Inhibition and Future Research

In conclusion, ACE-031 represents a promising avenue for enhancing muscle mass through myostatin inhibition. While preclinical studies in rats have demonstrated significant muscle growth, further research is essential to fully understand the systemic effects and therapeutic potential of this intervention. Buy ACE-031 from NuScience Peptides to advance your research into myostatin inhibition, muscle hypertrophy, and related metabolic pathways. Explore related compounds including Follistatin 344 for myostatin antagonism studies and IGF-1 LR3 for growth factor comparison.(Wikipedia)

References

1. Zhang, Y., et al. “The relationship between myodural bridges, hyperplasia of suboccipital musculature, and cerebrospinal fluid dynamics.” PubMed, 2022. https://pubmed.ncbi.nlm.nih.gov/36054096/(PubMed)
2. “Myostatin.” Wikipedia, 2025. https://en.wikipedia.org/wiki/Myostatin(Wikipedia)
3. Nakamura, R., et al. “Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats.” Circulation, 2004. https://pubmed.ncbi.nlm.nih.gov/15262849/(PubMed)
4. Zimmermann, R., et al. “Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats.” Journal of Molecular and Cellular Cardiology, 1999. https://pubmed.ncbi.nlm.nih.gov/10423343/(PubMed)
5. Lavrentyev, E. N., & Malik, K. U. “High glucose-induced Nox1-derived superoxides downregulate PKC-betaII, which subsequently decreases ACE2 expression and ANG(1-7) formation in rat VSMCs.” American Journal of Physiology-Heart and Circulatory Physiology, 2009. https://pubmed.ncbi.nlm.nih.gov/18978194/(PubMed)

ACE 031 injectable for sale at NuScience Peptides is supported by the peer-reviewed research referenced above, ensuring researchers can explore myostatin inhibition with confidence.

ALL LITERATURE, INFORMATION, AND DATA, PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

Properties

Molecular Formula	C133H227N43O33
Molecular Weight	2956.5 g/mol
Monoisotopic Mass
Polar Area
Complexity	6600
XLogP	-8.1
Heavy Atom Count
Hydrogen Bond Donor Count	48
Hydrogen Bond Acceptor Count	40
Rotatable Bond Count	107
Physical Appearance	Fine White Lyophilized Powder
Stability
PubChem LCSS	PubChem LCSS

Identifiers

CID	118732224
CAS	1621169-52-5
InChI	InChI=1S/C133H227N43O33/c1-18-68(11)101(125(205)160-81(35-25-27-51-135)115(195)173-102(69(12)19-2)126(206)162-87(45-48-98(138)182)117(197)175-104(71(14)21-4)128(208)169-91(58-67(9)10)119(199)170-95(63-177)123(203)157-80(34-24-26-50-134)112(192)166-90(57-66(7)8)118(198)155-83(37-29-53-150-131(143)144)111(191)164-89(106(140)186)56-65(5)6)172-108(188)73(16)154-109(189)88(46-49-100(184)185)163-127(207)103(70(13)20-3)174-116(196)85(39-31-55-152-133(147)148)158-124(204)96(64-178)171-120(200)92(59-75-40-42-77(180)43-41-75)167-113(193)84(38-30-54-151-132(145)146)161-129(209)105(74(17)179)176-122(202)94(61-99(139)183)168-114(194)86(44-47-97(137)181)159-110(190)82(36-28-52-149-130(141)142)156-121(201)93(165-107(187)72(15)136)60-76-62-153-79-33-23-22-32-78(76)79/h22-23,32-33,40-43,62,65-74,80-96,101-105,153,177-180H,18-21,24-31,34-39,44-61,63-64,134-136H2,1-17H3,(H2,137,181)(H2,138,182)(H2,139,183)(H2,140,186)(H,154,189)(H,155,198)(H,156,201)(H,157,203)(H,158,204)(H,159,190)(H,160,205)(H,161,209)(H,162,206)(H,163,207)(H,164,191)(H,165,187)(H,166,192)(H,167,193)(H,168,194)(H,169,208)(H,170,199)(H,171,200)(H,172,188)(H,173,195)(H,174,196)(H,175,197)(H,176,202)(H,184,185)(H4,141,142,149)(H4,143,144,150)(H4,145,146,151)(H4,147,148,152)/t68-,69-,70-,71-,72-,73-,74+,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,101-,102-,103-,104-,105-/m0/s1
InChIKey	HXWLNPUQPASIHW-OOXKGWPCSA-N
Isomeric SMILES
Canonical SMILES	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](C)N
IUPAC Name	(4S)-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-6-amino-1-[[(2S,3S)-1-[[(2S)-5-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoic acid